Furthermore, a question arose because of the low expression level of E-cadherin in benign prostatic hyperplasia [60], [61] and urothelial diseases [62], [63], which could also have resulted from the -160A polymorphism in the promoter region of E-cadherin. The gene discussed is CDH1; the disease is benign prostatic hyperplasia.